If you have been reading about Certificate of analysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-01. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual inspection of dry material |
| Solubility | Soluble in water | Polar aqueous solvent class |
| Typical storage | Minus 20 degrees Celsius, desiccated, dark | Applies to the lyophilized form |
| Purity assessment | Reversed-phase HPLC | Ultraviolet detection, area percent |
| Identity confirmation | Mass spectrometry | Measured mass compared with theoretical value |
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Treatment of established atherosclerotic disease may include medications to lower cholesterol such as statins, blood pressure medication, and anticoagulant therapies to reduce the risk of blood clot formation. As the disease state progresses, more invasive strategies are applied, such as percutaneous coronary intervention, coronary artery bypass graft, or carotid endarterectomy. In some individuals, genetic factors are also implicated in the disease process and cause a strongly increased predisposition to development of atherosclerosis. Atherosclerosis generally starts when a person is young and worsens with age. Almost all people are affected to some degree by the age of 65. It is the number one cause of death and disability in developed countries. Though it was first described in 1575, there is evidence suggesting that this disease state is genetically inherent in the broader human population, with its origins tracing back to CMAH genetic mutations that may have occurred more than two million years ago during the evolution of hominin ancestors of modern human beings.
=== Withdrawal === The relatively long half-lives of fluoxetine and its active metabolite norfluoxetine are believed to contribute to a lower risk of antidepressant discontinuation syndrome after stopping treatment, compared with shorter-acting agents such as paroxetine and venlafaxine. Although gradual dose reductions are recommended with antidepressants with shorter half-lives, tapering may not be necessary with fluoxetine. It has been recommended as a treatment option for antidepressant discontinuation syndrome.
=== Initial descriptions and discovery === One of the earliest recorded outbreaks of foodborne botulism occurred in 1793 in the village of Wildbad in what is now Baden-Württemberg, Germany. Thirteen people became sick and six died after eating pork stomach filled with blood sausage, a local delicacy. Additional cases of fatal food poisoning in Württemberg led the authorities to issue a public warning against consuming smoked blood sausages in 1802 and to collect case reports of "sausage poisoning". Between 1817 and 1822, the German physician Justinus Kerner published the first complete description of the symptoms of botulism, based on extensive clinical observations and animal experiments. He concluded that the toxin develops in bad sausages under anaerobic conditions, is a biological substance, acts on the nervous system, and is lethal even in small amounts. Kerner hypothesized that this "sausage toxin" could be used to treat a variety of diseases caused by an overactive nervous system, making him the first to suggest that it could be used therapeutically. In 1870, the German physician John Müller coined the term botulism to describe the disease caused by sausage poisoning, from the Latin word botulus, meaning 'sausage'. In 1895, Émile van Ermengem, a Belgian microbiologist, discovered what is now known as Clostridium botulinum and confirmed that a toxin produced by the bacteria causes botulism.
The Singapore government states that the death penalty is only used in the most serious of crimes, sending a strong message to potential offenders. They point out that in 1994 and 1999 the United Nations General Assembly failed to adopt United Nations resolutions calling for a moratorium on the death penalty worldwide, as a majority of countries opposed such a move. Singapore's permanent representative to the United Nations wrote a letter to the Special Rapporteur on extrajudicial, summary or arbitrary executions in 2001 which stated:
== Habitat == Brown recluse spiders build asymmetrical (irregular) webs that frequently include a shelter consisting of disorderly threads. They frequently build their webs in woodpiles and sheds, closets, garages, plenum spaces, cellars, and other places that are dry and generally undisturbed. When dwelling in human residences they seem to favor cardboard, possibly because it mimics the rotting tree bark which they inhabit naturally. Human-recluse contact often occurs when such isolated spaces are disturbed and the spider feels threatened. Unlike most web weavers, they leave these lairs at night to hunt. Males move around more when hunting than the females, which tend to remain nearer to their webs.
Sources: en.wikipedia.org
Each February, Tim Hortons holds a marketing campaign titled "Roll Up the Rim to Win". As of 2007, over 31 million prizes were distributed each year, including cars, televisions, and store products. Customers determine if they have won prizes by unrolling the rim on their paper cups when they have finished their drink, revealing the result underneath. Prizes are not distributed randomly country-wide; each of the company's distribution regions has distinct prize-winning odds. The idea for the campaign began in 1985 when Roger Wilson of one of Tim Hortons' supplier of cups, Lily Cup company, approached Tim Hortons with a new idea to increase their sales. Wilson explained his company had created a new cup design that allowed a message to be printed under the rim; the cup type cost no more than the current one and could enable a promotion or contest. Recognizing the opportunity to promote coffee in the normally weak sales period in the spring, the Roll Up the Rim to Win campaign was first held in 1986 when the biggest prize was a snack box of Timbits. In 2008, over 88% of major prizes were redeemed. The contest is popular enough that Paul Kind invented the Rimroller (as seen on Dragons' Den), a device for rolling up the rim mechanically. The contest has seen several controversies including the theft of unrolled cups. In March 2006, two families were fighting over a Toyota RAV4 SUV prize of CA$32,000 value when their daughters found a winning "roll up the rim" coffee cup in a garbage bin of an elementary school in Saint-Jérôme, Quebec.
=== Netherlands === In 2007, four food technology students in the Netherlands invented a powdered alcohol product called "Booz2go". They claimed that when mixed with water, the powder would produce a bubbly, lime-colored and lime-flavored drink, with 3% alcohol. When put into commercial production, it was expected to sell for €1.50 (approx. US$1.60) for a 20 gram sachet. The product's creators and marketers – Harm van Elderen, Martyn van Nierop, and others at Helicon Vocational Institute in Boxtel – claimed to be aiming at the youth market. They compared the drink to alcopops like Bacardi Breezer and said they expected the relatively low alcohol content would be popular with the young segment. Because of complexities in Dutch laws, powdered alcohol like Booz2Go would not be subject to the Alcohol and Horeca Code, because it is not literally an alcoholic drink. This means that anybody of any age could buy it legally. However, when dissolved in water, it would be subject to the Code, according to Director Wim van Dalen of the Dutch National Foundation for Alcohol Prevention. Von Dalen commented that while he generally did not support new alcoholic drinks, he doubted the powder would become attractive. A spokesman of the Ministry of Health, Welfare and Sport said they would not undertake any actions against the product, but added that the label would have to contain a warning about any health risks for the consumer, in accordance with other laws. In 2014, Booz2go is not yet commercially available.
==== Hormone deficiency ==== Children with primary adrenal failure, also called Addison's disease, may experience hypoglycemia after long periods of fasting. Addison's disease is associated with chronically low levels of the stress hormone cortisol, which leads to decreased glucose production. Hypopituitarism, leading to decreased growth hormone, is another cause of hypoglycemia in children, particularly with long periods of fasting or increased exercise.
"It seems to me", Mellanby wrote to Florey, "that the line of work you are suggesting will be interesting and may prove to be of practical importance." Florey felt that far more would be required. On 1 November 1939, Henry M. "Dusty" Miller Jr from the Natural Sciences Division of the Rockefeller Foundation paid Florey a visit. Miller encouraged Florey to apply for funding from the foundation and supported his application. "The work proposed", Florey wrote in the application letter, "in addition to its theoretical importance, may have practical value for therapeutic purposes." His application was approved, with the foundation allocating US$5,000 (£1,250) per annum for five years. The Oxford team's first task was to obtain a sample of penicillin mould. This turned out to be easy. Georges Dreyer, Florey's predecessor, had obtained a sample of the mould in 1930 for his work on bacteriophages, viruses that infect bacteria. Dreyer had lost interest in penicillin when he discovered that it was not a bacteriophage, but he had continued to cultivate it. Dreyer had died in 1934, but Campbell-Renton had continued to culture the mould and was able to supply it to the Oxford team. The next task was to grow sufficient mould to extract enough penicillin for laboratory experiments. The mould was cultured on a surface of liquid Czapek-Dox medium. Over the course of a few days it formed a yellow gelatinous skin covered in green spores. Beneath this, the liquid became yellow and contained penicillin. The team determined that the maximum yield was achieved in ten to twenty days.
Ember was an American company based in Boston, Massachusetts, USA, which is now owned by Silicon Labs. Ember had a radio development centre in Cambridge, England, and distributors worldwide. It developed Zigbee wireless networking technology that enabled companies involved in energy technologies to help make buildings and homes smarter, consume less energy, and operate more efficiently. The low-power wireless technology can be embedded into a wide variety of devices to be part of a self-organizing mesh network. All Ember products conform to IEEE 802.15.4-2003 standards. In May 2012, Ember was acquired by Silicon Labs.
Sources: en.wikipedia.org
Dry powder is commonly held at minus twenty degrees Celsius, desiccated and away from light. Cold storage slows degradation of the lyophilized material.
Mass spectrometry establishes the molecular mass, and reversed-phase chromatography reports purity. A certificate of analysis typically combines both results.
Solutions degrade faster than the dry powder, particularly at room temperature. Portioning into single-use aliquots and freezing reduces losses from repeated thawing.
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.